Expert Review of Anticancer Therapy This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis
CONCLUSIONS: We found a strong association between treatment effects for EFS and OS, indicating that improvements in EFS are likely to be predictive of improvements in OS. EFS may therefore be a reliable surrogate for OS after neoadjuvant therapy in r-NSCLC.PMID:37850939 | DOI:10.1080/14737140.2023.2272645 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - October 18, 2023 Category: Cancer & Oncology Authors: Gyula Ostoros Robert Hettle Nefeli Georgoulia Mehmet Berktas Pratibha Chander Ignacio Diaz Perez Anne-Marie Couto Christian Eichinger Polly Field Peter Morten Source Type: research

The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities and future directions
Expert Rev Anticancer Ther. 2023 Oct 18. doi: 10.1080/14737140.2023.2271662. Online ahead of print.ABSTRACTINTRODUCTION: Nelarabine is a guanine nucleoside analog and functions to terminate DNA synthesis in dividing cells. Pre-clinical and clinical studies have shown that it preferentially accumulates in T-cells where it exerts its cytotoxic effects. After generations of treatment protocol advances, it has been incorporated into numerous treatment regimens against T-lineage acute lymphoblastic leukemia/lymphoma (T-ALL/LLy). On 8 March 2023, the FDA approved the use of nelarabine for its use in T-ALL due to clear evidence o...
Source: Expert Review of Anticancer Therapy - October 18, 2023 Category: Cancer & Oncology Authors: Lane H Miller Kim L Maxa Stuart S Winter Nathan P Gossai Source Type: research

Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy
Expert Rev Anticancer Ther. 2023 Oct 16:1-13. doi: 10.1080/14737140.2023.2270161. Online ahead of print.ABSTRACTINTRODUCTION: Prognosis of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) remains disappointing with a 5-year overall survival of only 3-5%. Compared to other cancers, the evolution in standard therapeutic options has been stagnant and polychemotherapy regimens (with well-known toxicity profile and resistance pattern) remain standard of care. Only for patients (5%-7%) with a breast cancer gene (BRCA) pathogenic germline variant, prognosis has improved by the use of olaparib (poly-ADP ribose pol...
Source: Expert Review of Anticancer Therapy - October 16, 2023 Category: Cancer & Oncology Authors: Barbara Geerinckx Laure-Anne Teuwen Tiffany Foo Timon Vandamme Annabel Smith Marc Peeters Timothy Price Source Type: research

Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy
Expert Rev Anticancer Ther. 2023 Oct 16. doi: 10.1080/14737140.2023.2270161. Online ahead of print.ABSTRACTINTRODUCTION: Prognosis of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) remains disappointing with a 5-year overall survival of only 3-5%. Compared to other cancers, the evolution in standard therapeutic options has been stagnant and polychemotherapy regimens (with well-known toxicity profile and resistance pattern) remain standard of care. Only for patients (5%-7%) with a Breast cancer gene (BRCA) pathogenic germline variant, prognosis has improved by the use of olaparib (poly-ADP ribose polymera...
Source: Expert Review of Anticancer Therapy - October 16, 2023 Category: Cancer & Oncology Authors: Barbara Geerinckx Laure-Anne Teuwen Tiffany Foo Timon Vandamme Annabel Smith Marc Peeters Timothy Price Source Type: research

Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature
Expert Rev Anticancer Ther. 2023 Oct 9:1-12. doi: 10.1080/14737140.2023.2267760. Online ahead of print.ABSTRACTINTRODUCTION: Leukemia is an abnormal clonal development of leukemic cells originating from the bone marrow, which is widely known for its significant prevalence and mortality rate. Chemotherapy, surgery, radiation, and combination therapies have been its routine therapeutic methods; however, the advent of cancer immunotherapy is known as revolutionary for its higher efficacy and lesser toxicity.AREAS COVERED: Immunotherapy boosts the body's immune system by using components from other living organisms. Although i...
Source: Expert Review of Anticancer Therapy - October 9, 2023 Category: Cancer & Oncology Authors: Kimia Kazemzadeh Sadra Behrouzieh Nima Rezaei Source Type: research